within Pharmacolibrary.Drugs.ATC.R;

model R06AE05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.42,
    Cl             = 0.001,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.006,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00028333333333333335,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>R06AE05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Meclozine (also known as meclizine) is an antihistamine of the piperazine class, primarily used to treat motion sickness and vertigo associated with diseases affecting the vestibular system. It is approved and available as an over-the-counter medication for motion sickness and as a prescription drug for vertigo.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult subjects; direct human pharmacokinetic data is not published in peer-reviewed literature. Parameters are estimated based on available drug monographs and class-related pharmacokinetics.</p><h4>References</h4><ol><li><p>Matsushita, M, et al., &amp; Kitoh, H (2017). Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia. <i>Scientific reports</i> 7(1) 7371–None. DOI:<a href=\"https://doi.org/10.1038/s41598-017-07044-8\">10.1038/s41598-017-07044-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28785080/\">https://pubmed.ncbi.nlm.nih.gov/28785080</a></p></li><li><p>Clissold, SP, &amp; Heel, RC (1985). Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy. <i>Drugs</i> 29(3) 189–207. DOI:<a href=\"https://doi.org/10.2165/00003495-198529030-00001\">10.2165/00003495-198529030-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3886352/\">https://pubmed.ncbi.nlm.nih.gov/3886352</a></p></li><li><p>Nachum, Z, et al., &amp; Gordon, CR (2006). Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. <i>Clinical pharmacokinetics</i> 45(6) 543–566. DOI:<a href=\"https://doi.org/10.2165/00003088-200645060-00001\">10.2165/00003088-200645060-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16719539/\">https://pubmed.ncbi.nlm.nih.gov/16719539</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end R06AE05;
